Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MLNR | O43193 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troleandomycin SCHEMBL125070 | 0.89 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Troleandomycin SCHEMBL125071 | 0.89 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Troleandomycin SCHEMBL29470683 | 0.89 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Troleandomycin SCHEMBL664623 | 0.89 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Troleandomycin SCHEMBL28198745 | 0.87 | CYP3A4 (0.94) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Diproleandomycin SCHEMBL2109038 | 0.80 | CYP3A4 (0.78) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Troleandomycin SCHEMBL3065803 | 0.79 | CYP3A4 (0.79) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Oleandomycin SCHEMBL10028439 | 0.75 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Oleandomycin SCHEMBL3717 | 0.75 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 | |
| Oleandomycin SCHEMBL3716 | 0.75 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227208-A1 | COSMETIC COMPOSITIONS CONTAINING SUBSTITUTED AZOLE AND METHODS FOR ALLEVIATING MECHANICALLY-INDUCED SKIN INFLAMMATION | THE PROCTER & GAMBLE COMPANY (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140227208-A1 | COSMETIC COMPOSITIONS CONTAINING SUBSTITUTED AZOLE AND METHODS FOR ALLEVIATING MECHANICALLY-INDUCED SKIN INFLAMMATION | THE PROCTER & GAMBLE COMPANY (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227208-A1 | COSMETIC COMPOSITIONS CONTAINING SUBSTITUTED AZOLE AND METHODS FOR ALLEVIATING MECHANICALLY-INDUCED SKIN INFLAMMATION | CUTA, KRT18, IL33 | CYP3A4 97/4885USP2 3147/4885ABCB1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.